Amid a push to resolve opioid and talc claims, Johnson & Johnson settles Risperdal litigation for $800M

Over the last few months, Johnson & Johnson has made sweeping moves to resolve a mountain of litigation involving the safety and marketing of its opioid and talc products. Friday brought word of a lower-profile resolution, as J&J revealed it has settled liability claims surrounding its antipsychotic drug Risperdal.

The $800 million settlement was struck in September and resolves “substantially all of the outstanding cases in the United States,” the company revealed in a Securities and Exchange Commission filing. The agreement resolves approximately 9,000 cases the company faced from those who claimed Risperdal caused breast tissue development in males, a condition called gynecomastia.

RELATED: Johnson & Johnson puts talc headache into bankruptcy; plaintiffs will contest the ploy

Risperdal was approved in 1993 for schizophrenia and bipolar mania in adults. In 2006, it was sanctioned to treat irritability in children associated with autism.

In 2019, a Philadelphia jury awarded a whopping $8 billion in punitive damages to Nicholas Murray, a Maryland man who developed breasts because of his use of Risperdal. Three months later, a judge trimmed the award to $6.8 million. Murray, who took Risperdal for autism spectrum disorder, claimed in 2013 that J&J aggressively marketed the drug and didn’t warn of its risks.

That same year, J&J agreed to pay $2.2 billion to settle a federal probe into its off-label marketing of Risperdal and two other drugs.

RELATED: Jury smacks J&J with $8B Risperdal verdict, but will it stand up in appeals?

The settlement comes amid a flurry of legal maneuverings by J&J. In July, the company—along with distributors AmerisourceBergen, Cardinal Health and McKesson—agreed to pay $26 billion to resolve thousands of opioid lawsuits in the U.S.

That deal has yet to be finalized, and J&J has continued to pursue settlements with individual states. Last week, the company agreed to a $297 million settlement with Texas, the amount of which will be deducted from what J&J owes in the national settlement.

RELATED: Done deal: Johnson & Johnson and 3 distributors agree to historic $26 billion opioid settlement

Two weeks ago, J&J filed for bankruptcy protection for its newly created subsidiary, LTL Management, which was established to manage lawsuits representing more than 30,000 women who claim J&J’s talc products cause cancer.

Lawyers representing the plaintiffs have said they will oppose the ploy, known as the Texas two-step, which has been used in the past to minimize losses from asbestos claims.